(Yana Iskayeva/Moment/Getty Images) Alzheimer's disease is an incredibly challenging condition to study, because of both its ...
3don MSN
An Alzheimer’s Drug Cut Expected Cognitive Decline Roughly in Half. It Didn’t Target Amyloid
Researchers say the oral drug LM11A-31 slowed the decline of brain-network function in a small trial, pointing to a potential ...
An estimated 50 million people worldwide have dementia, with Alzheimer's disease—accounting for more than 70%—being the representative neurodegenerative brain disorder. A Korean research team has, for ...
In Alzheimer's disease, amyloid plaques form in the brain, followed by threadlike structures made of the protein tau. Both changes have toxic effects on the brain's nerve cells years before dementia ...
The accumulation and transformation of amyloid proteins form the central pathological hallmark of Alzheimer’s disease. Proteolytic processing of the amyloid precursor protein (APP) by β-secretase and ...
ScienceAlert on MSN
Experimental Alzheimer's Treatment Restores Two Hours of Sleep When Tested in Mice
(Ktsimage/iStock/Getty Images Plus) Alzheimer's disease is such a challenging condition to study because it presents ...
Recently FDA-approved treatments work to clear clumps of the protein amyloid beta in the brain. A drug that instead goes after tangles of the protein tau can yield similar cognitive outcomes, a new st ...
The tiny protein known as transthyretin can cause big problems in the body when it misfolds after secretion. While healthy transthyretin moves hormones through blood and spinal fluid, misfolded ...
A recent study led by a team of researchers at The Johns Hopkins University School of Medicine examining aging mice has provided what is believed to be the first evidence that amyloid beta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results